Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are significant causes of morbidity and mortality in rheumatic diseases.
• Current treatments offer limited survival benefits due to complex pathogenic mechanisms involving both immune and non-immune cells.
• The ineffectiveness of immunosuppressive therapy highlights the need for novel treatment strategies.

Purpose of the Study:

• To review the epidemiologic features of ILD and PAH in patients with rheumatic diseases.
• To discuss current and emerging state-of-the-art treatment options.
• To focus on the role of targeted agents in managing these conditions.

Main Methods:

• Literature review of epidemiologic data and treatment strategies.
• Analysis of clinical trial results for targeted agents.
• Focus on biologics, antifibrotic agents, and vasodilatory drugs.

Main Results:

• Rheumatic diseases like rheumatoid arthritis, myositis, and systemic sclerosis are associated with ILD and PAH.
• Targeted agents have demonstrated promising results in recent clinical trials for ILD and PAH.
• New therapeutic approaches offer potential for improved patient survival and management.

Conclusions:

• ILD and PAH represent critical challenges in rheumatic disease management.
• Targeted therapies, including biologics and antifibrotics, are emerging as effective treatment options.
• Further research into targeted agents is crucial for optimizing patient care and outcomes.